title: High-dose therapy and autologous stem cell transplantation for Hodgkin's lymphoma in relapse or failure after initial chemotherapy : results of the Centre National de Greffe de Moelle Osseuse de Tunis.
abstract: OBJECTIVE
  In the present study we report the clinical outcome of 27 patients with refractory or relapsed Hodgkin's lymphoma (HL) undergoing autologous peripheral stem-cell transplantation (ASCT).
  
  
  METHODS
  On transplant, 18 patients had sensitive disease (SD) and 9 resistant disease (RD). The median time between diagnosis and ASCT was 18 months (range, 7 to 96 months). The conditioning consisted of BEAM regimen.
  
  
  RESULTS
  The 100-day mortality rate was 3%. Three months after transplant, 12 patients transplanted with SD were in complete remission (CR) and only one of the 9 patients transplanted with RD achieved CR. Overall survival and disease-free survival after 3 years were 68% and 60%, respectively.
  
  
  CONCLUSIONS
  the present results confirm the efficacy and safety of the ASCT in refractory or relapsed HL patients with SD. Other strategies should be investigated for patients with RD.
authors.affiliation: Centre National de Greffe de Moelle Osseuse, Tunis.
authors.forename: Lamia
authors.initials: L
authors.lastname: Torjman
authors.forename: Saloua
authors.initials: S
authors.lastname: Ladeb
authors.forename: Amel
authors.initials: A
authors.lastname: Lakhal
authors.forename: Tarek
authors.initials: T
authors.lastname: Ben Othman
authors.forename: Abderrahman
authors.initials: A
authors.lastname: Abdelkefi
authors.forename: Abdeladhim
authors.initials: A
authors.lastname: Ben Abdeladhim
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002330:Carmustine / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use; D003627:Data Interpretation, Statistical; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use; D009367:Neoplasm Staging; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects; D012008:Recurrence; D012074:Remission Induction; D013997:Time Factors; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D003561:Cytarabine; D005047:Etoposide; D008558:Melphalan; D002330:Carmustine